Neoplasm Treatment - South Korea
South Korea- In South Korea, the Neoplasm Treatment market is projected to generate revenue of US$5.01bn in 2024.
- It is expected to experience an annual growth rate (CAGR 2024-2029) of 5.46%, which will result in a market volume of US$6.54bn by 2029.
- When compared globally, United States is anticipated to generate the highest revenue in this market, with an estimated US$90.56bn in 2024.
- South Korea's neoplasm treatment market is witnessing a surge in innovative technologies and precision medicine advancements.
Definition:
Neoplasm Treatment refers to the medical and surgical treatments of cancer patients who require hospitalization for their care. This includes surgeries, chemotherapy, radiation therapy, immunotherapy, and/or other treatments that require close monitoring and support from healthcare professionals. Patients will typically stay in a hospital for several days to several weeks, depending on the severity of their condition. This allows hospitals to provide the highest level of medical support and to help manage symptoms and/or side effects of the patients while they receive treatment.
Additional information:
The Neoplasm Treatments market comprises revenues and average revenue per capita. Market values represent revenues paid to hospitals by the respective healthcare payers (including VAT, if applicable). Reported market revenues include spending by consumers (B2C), enterprises (B2B), and governments (B2G). Revenues are allocated to the country where the money is spent.
In-Scope
- Inpatient treatment of cancer patients
Out-Of-Scope
- Long-term rehabilitative care
- Home-based rehabilitative care
